# Orion, Orion Pharma

Source: https://onco.cc/companies/orion-orion-pharma/  
OnCo record `orion-orion-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Orion, Orion Pharma is a Finland-based pharmaceutical company running 4 late-stage cancer trials of ODM-212, ODM-216 and sotorasib in mesothelioma, pancreatic ductal adenocarcinoma and non-small-cell lung cancer.

## Summary

Orion, Orion Pharma, based in Espoo, Finland, is a pharmaceutical company. Orion Pharma is a Finnish pharmaceutical company that develops and manufactures medicines across oncology, respiratory disease, neurological disease, women's health and pain management, as well as veterinary medicines and active pharmaceutical ingredients. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing ODM-212, ODM-216, sotorasib and ODM-208 in mesothelioma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer and prostate cancer. The largest, NCT06725758 (A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours), plans to enrol 315 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Orion Corporation, Orion Pharma
- Tags: ctgov-sponsor
- HQ: Espoo
- Type: pharma
- Website: https://www.orionpharma.com

## Sources

- Official website: https://www.orionpharma.com
- ClinicalTrials.gov: trials led by Orion, Orion Pharma: https://clinicaltrials.gov/search?lead=Orion%20Corporation%2C%20Orion%20Pharma

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- trials: [A 2-part Phase 1/2 Open-label Trial on ODM-212](https://onco.cc/trials/nct07563738/), [A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours](https://onco.cc/trials/nct06725758/), [Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct03436485/), [Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer](https://onco.cc/trials/nct07805252/)

---
JSON: https://onco.cc/api/v1/entities/orion-orion-pharma.json